Product Information
CHOLESTYRAMINE PACKET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.8343 per EA under NDC 68382052860. Its NADAC has been published 401 times since Nov 7, 2018.
FDA first approved this application on Jul 2, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 g/9g
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382052860
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CHOLESTYRAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA202901FDA Approved
7/2/2018
TE Code
AB
On Market Since
8/1/2018
Pharmacological Classes
Price Statistics
The NADAC for CHOLESTYRAMINE PACKET has been published 401 times since Nov 7, 2018, and over the history we have for it it has declined 42.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8343 per EA |
|---|---|
| All-time high | $1.4925 (Jul 10, 2019) |
| All-time low | $0.5806 (Apr 17, 2024) |
| 52-week high | $0.9390 |
| 52-week low | $0.6721 |
| Median price | $1.0677 |
| Average price | $1.0645 |
| Largest weekly change | +34.2% (Jun 19, 2024) |
| Weeks tracked | 401 |
| Tracking since | Nov 7, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CHOLESTYRAMINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bile Acid Sequestrant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHOLESTYRAMINE PACKET?
The current National Average Drug Acquisition Cost (NADAC) for CHOLESTYRAMINE PACKET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.8343 per EA (NDC 68382052860), effective Sep 30, 2026.
How has the price of CHOLESTYRAMINE PACKET changed over time?
Over the history we have for it, the NADAC for CHOLESTYRAMINE PACKET has declined 42.1%. It has been tracked across 401 weekly CMS publications since Nov 7, 2018.
What are the highest and lowest recorded NADAC prices for CHOLESTYRAMINE PACKET?
Since Nov 7, 2018, the NADAC for CHOLESTYRAMINE PACKET has ranged from a low of $0.5806 (Apr 17, 2024) to a high of $1.4925 (Jul 10, 2019), with a median of $1.0677 per EA.
Are there cheaper alternatives to CHOLESTYRAMINE PACKET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHOLESTYRAMINE LIGHT PACKET, is $0.8327 per EA — about 0% below CHOLESTYRAMINE PACKET.
Who manufactures CHOLESTYRAMINE PACKET?
CHOLESTYRAMINE PACKET (NDC 68382052860) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.